| Steven Joseph Holladay, OTRL | |
|
9630 Grove Cir N Ste 200, Maple Grove, MN 55369-3492 | |
| (763) 520-7870 | |
| (763) 520-7580 |
| Full Name | Steven Joseph Holladay |
|---|---|
| Gender | Male |
| Speciality | |
| Experience | Years |
| Location | 9630 Grove Cir N Ste 200, Maple Grove, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154911949 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | 105876 (Minnesota) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Steven Joseph Holladay, OTRL 9630 Grove Cir N Ste 200, Maple Grove, MN 55369-3492 Ph: (763) 520-7870 | Steven Joseph Holladay, OTRL 9630 Grove Cir N Ste 200, Maple Grove, MN 55369-3492 Ph: (763) 520-7870 |
News Archive
Researchers from Johns Hopkins have found that dense mats of interacting bacteria, called biofilms, were present in the majority of cancers and polyps, particularly those on the right side of the colon. The presence of these bacterial bunches, they say, may represent an increased risk for colon cancer and could form the basis of new diagnostic tests.
The next time you are stung by a bee, here's some consolation: a toxic protein in bee venom, when altered, significantly improves the effectiveness liposome-encapsulated drugs or dyes, such as those already used to treat or diagnose cancer. This research, described in the August 2010 print issue of the FASEB Journal, shows how modified melittin may revolutionize treatments for cancer and perhaps other conditions, such as arthritis, cardiovascular disease, and serious infections.
Four-year results of the Zilver PTX Randomized Controlled Trial of Paclitaxel-Eluting Stents for Femoropopliteal Disease continue to demonstrate consistent, superior results when compared to bare metal stents (BMS) and percutaneous transluminal angioplasty (PTA) in terms of primary patency, restenosis reduction and revascularization rates.
Exelixis, Inc. has submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) for XL999, a proprietary novel anticancer compound.
› Verified 4 days ago
Ms. Renee Haroldson, OTRL CHT Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 14500 99th Ave N, #1-210, Maple Grove, MN 55369 Phone: 763-898-1778 Fax: 763-898-1771 | |
Jennifer Alders, Occupational Therapist Medicare: Medicare Enrolled Practice Location: 6936 Garland Ln N, Maple Grove, MN 55311 Phone: 763-416-9313 Fax: 763-416-4530 | |
Mark A Narveson, O.T. Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 7767 Elm Creek Blvd N Ste 160, Maple Grove, MN 55369 Phone: 763-201-8191 | |
Heather Renee Elder, OTR/L Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 7767 Elm Creek Blvd N Ste 160, Maple Grove, MN 55369 Phone: 763-201-8191 Fax: 763-201-8192 | |
Mrs. Cheryl Anne Salim, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 16500 92nd Ave N, Maple Grove, MN 55311 Phone: 763-493-5910 | |
Megan Kay Holmgren, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 6936 Garland Ln N, Maple Grove, MN 55311 Phone: 763-416-9313 | |
Inga Rohde, Occupational Therapist Medicare: Medicare Enrolled Practice Location: 11100 86th Ave N, Maple Grove, MN 55369 Phone: 763-755-4275 |